Dr. Jianguo Lin, Researcher/Professor, PhD Supervisor Director of Innovative Drug Research Center Tel: 0510-85514482-2301 E-mail: linjianguo@jsinm.org | Innovative Drug Research Center (IDRC) is one of key laboratories in Jiangsu Institute of Nuclear Medicine. There are six staffs in the IDRC, and Dr. Jianguo Lin is the director of IDRC, titled with Researcher/Professor and Doctoral supervisor. Three staffs were selected as Jiangsu Provincial “333 High-level Talent Training Project”, two staffs selected as Jiangsu Provincial “Top Medical Talent”, and one staff selected as Jiangsu Provincial Key Medical Talent. Besides, there are two doctoral students and eighteen postgraduate students in our lab. IDRC dedicates to the development of novel diagnostic and therapeutic radiopharmaceuticals, providing new methods and techniques for accurate diagnosis, treatment and efficacy evaluation of tumor, nervous system, and other diseases. The center mainly focuses on the following three directions: (1) Development of novel tumor targeting molecular probes; (2) Development of novel neurodegenerative diseases targeting molecular probes; (3) Development of novel multifunctional theranostic agents for diagnosis and treatment of diseases. In the past decade, IDRC has achieved outstanding performance in scientific research. More than 100 papers have been published in well-known journals, such as J Am Chem Soc, Angew Chem Int Ed, J Nucl Med, Eur J Nucl Med Mol I, Chinese Journal of Nuclear Medicine and Molecular Imaging, and so on. Thirty-four national invention patents and four utility model patents have been granted. The center has established close cooperation with many research groups home and abroad. Warmly welcome students and scholars with diverse backgrounds and expertise in Chemistry, Biochemistry, Pharmacology, Molecular Biology, Neurobiology, Materials Science, Bioinformatics, Bioengineering, Medical Imaging and Nuclear Medicine to join our group for further training and communication. Doctors and postdocs with the research background in radiopharmaceuticals and molecular probes are especially welcome to join the center and make progress together. |